From: Eosinophilia in critically ill COVID-19 patients: a French monocenter retrospective study
Patients with eosinophilia during ICU stay N = 26 | |
---|---|
Eosinophil count at ICU admission | |
Median eosinophils count (cell/mm3) | 5 [0–20] |
Eosinophilia (> 500/mm3) | 1 (4) |
Eosinopenia (< 40/mm3) | 22 (85) |
No eosinophil | 13 (50) |
Normal eosinophil count | 3 (11) |
Eosinophilia during ICU stay | |
Days between ICU admission and eosinophilia | 19 [13–28] |
Days between disease onset and eosinophilia | 30 [23–38] |
Days between disease onset and pic of eosinophilia | 31 [25–42] |
Median eosinophil count (cells/mm3) | 900 [678–1350] |
Severe eosinophilia (> 1500/mm3) | 6 (23) |
Total duration of eosinophilia (days) | 5 [3–12] |
Biphasic eosinophilia | 7 (27) |
Administration of β-lactam antibiotics during eosinophilia period | 10 (38) |
Temperature > 38.3 °C at least once during eosinophilia period | 11 (42) |
Erythematous skin rash during the eosinophilia period | 2 (8) |
Treatment with ivermectin for eosinophilia | 3 (12) |